Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology

It is strongly suggested that dipeptidyl peptidase‐4 inhibitors are associated with increased risk of bullous pemphigoid onset, especially in the elderly. Heightened clinical vigilance for bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor use is required in daily diabetes care.[Ima...

Descripción completa

Detalles Bibliográficos
Autores principales: Murakami, Takaaki, Yabe, Daisuke, Inagaki, Nobuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717917/
https://www.ncbi.nlm.nih.gov/pubmed/30989811
http://dx.doi.org/10.1111/jdi.13060
_version_ 1783447640531271680
author Murakami, Takaaki
Yabe, Daisuke
Inagaki, Nobuya
author_facet Murakami, Takaaki
Yabe, Daisuke
Inagaki, Nobuya
author_sort Murakami, Takaaki
collection PubMed
description It is strongly suggested that dipeptidyl peptidase‐4 inhibitors are associated with increased risk of bullous pemphigoid onset, especially in the elderly. Heightened clinical vigilance for bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor use is required in daily diabetes care.[Image: see text]
format Online
Article
Text
id pubmed-6717917
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-67179172019-09-06 Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology Murakami, Takaaki Yabe, Daisuke Inagaki, Nobuya J Diabetes Investig Commentaries It is strongly suggested that dipeptidyl peptidase‐4 inhibitors are associated with increased risk of bullous pemphigoid onset, especially in the elderly. Heightened clinical vigilance for bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor use is required in daily diabetes care.[Image: see text] John Wiley and Sons Inc. 2019-05-14 2019-09 /pmc/articles/PMC6717917/ /pubmed/30989811 http://dx.doi.org/10.1111/jdi.13060 Text en © 2019 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Commentaries
Murakami, Takaaki
Yabe, Daisuke
Inagaki, Nobuya
Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology
title Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology
title_full Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology
title_fullStr Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology
title_full_unstemmed Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology
title_short Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology
title_sort bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: clinical features and pathophysiology
topic Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717917/
https://www.ncbi.nlm.nih.gov/pubmed/30989811
http://dx.doi.org/10.1111/jdi.13060
work_keys_str_mv AT murakamitakaaki bullouspemphigoidwithdipeptidylpeptidase4inhibitorsclinicalfeaturesandpathophysiology
AT yabedaisuke bullouspemphigoidwithdipeptidylpeptidase4inhibitorsclinicalfeaturesandpathophysiology
AT inagakinobuya bullouspemphigoidwithdipeptidylpeptidase4inhibitorsclinicalfeaturesandpathophysiology

Ejemplares similares